肝硬化失代偿模式的新临床与预后特征
研究纳入意大利两家三级中心的617例肝硬化门诊患者,2003年1月至2021年6月前瞻性随访至研究结束、死亡或肝移植。随访中154例(25.0%)出现并发症,其中69例(44.8%)为非急性失代偿(NAD),85例(55.2%)为急性失代偿(AD);NAD患者中29例(42.0%)后续发生AD。无失代偿患者60个月生存率显著高于NAD或AD患者。多变量分析显示AD(HR 21.07,p<0.001)、NAD(HR 7.13,p<0.001)、肝硬化病因治愈(HR 0.38,p<0.001)和终末期肝病模型评分(HR 1.12,p=0.003)为死亡独立预测因素。
要点
- 门诊肝硬化患者中近50%的首次失代偿为NAD。
- NAD患者60个月生存率显著低于无失代偿患者。
- NAD是死亡的独立预测因素(HR 7.13,p<0.001)。
核心结论
- 门诊肝硬化患者首次失代偿近50%为非急性,但NAD仍与较无失代偿更低的生存率相关。
- 发生NAD的患者必须极其谨慎地治疗并密切监测以预防AD发生。
研究设计与样本
- 前瞻性研究,纳入意大利两家三级中心(帕多瓦和米兰)617例肝硬化门诊患者,2003年1月至2021年6月入组,随访至研究结束、死亡或肝移植。
主要发现
- 随访期间154例(占总患者25.0%)出现并发症,其中69例(44.8%)发生NAD,85例(55.2%)发生AD。
- NAD患者中29例(42.0%)在随访期间发生进一步AD。
- 无失代偿患者60个月生存率显著高于NAD或AD患者。
- 多变量分析中AD(HR 21.07,p<0.001)、NAD(HR 7.13,p<0.001)、肝硬化病因治愈(HR 0.38,p<0.001)和终末期肝病模型评分(HR 1.12,p=0.003)为死亡的独立预测因素。
临床怎么用
- 作者认为发生NAD的患者必须极其谨慎地治疗并密切监测以预防AD发生和降低死亡率。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The prognostic impact of acute decompensation (AD), i.e. the development of complications that require hospitalization, has recently been assessed. However, complications of cirrhosis do not necessarily require hospitalization and can develop progressively, as in the recently defined non-acute decompensation (NAD). Nevertheless, there is no data regarding the incidence and prognostic impact of NAD. The aim of the study was to evaluate the incidence and the prognostic impact of NAD and AD in outpatients with cirrhosis. METHODS: A total of 617 outpatients with cirrhosis from two Italian tertiary centers (Padua and Milan) were enrolled from January 2003 to June 2021 and followed prospectively until the end of the study, death or liver transplantation. The complications registered during follow-up were considered as AD if they required hospitalization, or NAD if managed at the outpatient clinic. RESULTS: During follow-up, 154 patients (25.0% of total patients) developed complications, 69 patients (44.8%) developed NAD and 85 (55.2%) developed AD, while 29 patients with NAD (42.0%) developed a further episode of AD during follow-up. Sixty-month survival was significantly higher in patients with no decompensation than in patients with NAD or AD. On multivariable analysis, AD (hazard ratio [HR] 21.07, p <0.001), NAD (HR 7.13, p <0.001), the etiological cure of cirrhosis (HR 0.38, p <0.001) and model for end-stage liver disease score (HR 1.12, p = 0.003) were found to be independent predictors of mortality. CONCLUSIONS: The first decompensation is non-acute in almost 50% of outpatients, though such events are still associated with decreased survival compared to no decompensation. Patients who develop NAD must be treated with extreme care and monitored closely to prevent the development of AD. IMPACT AND IMPLICATIONS: This multicenter study is the first to investigate the role of non-acute decompensation (NAD) in patients with cirrhosis. In fact, while the unfavorable impact of acute decompensation is well known, there is currently a dearth of evidence on NAD, despite it being a common occurrence in clinical practice. Our data show that almost half of decompensations in patients with cirrhosis can be considered NAD and that such events are associated with a higher risk of mortality than no decompensation. This study has important clinical implications because it highlights the need to carefully consider patients who develop NAD, in order to prevent further decompensation and reduce mortality.
引用
- Tonon M, D'Ambrosio R, Calvino V, et al. A new clinical and prognostic characterization of the patterns of decompensation of cirrhosis. J Hepatol. 2023. PMID: 38110003. doi:10.1016/j.jhep.2023.12.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。